insights_auto
Why is DRREDDY up 2,71%?
Dive Deeperchevron_right
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
1 229,40 INR
arrow_upward
+2,71%(+32,40) 1D
12-окт., 15:30:00 GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRREDDY...
Open
1 197,00 INR
High
1 235,00 INR
Low
1 196,90 INR
Mkt. cap
1,02 трлн
Avg. vol.
1,79 млн
Volume
1,76 млн
Dividend
0,65%
Quarterly dividend
2,00 INR
Ex-dividend date
2026-ж., 10-июл.
P/E ratio
31,79
52-wk high
1 414,90 INR
52-wk low
1 101,00 INR
EPS
38,67 INR
Shares outstanding
166,06 млн
No. of employees
28 миң
Open
1 197,00 INR
High
1 235,00 INR
Low
1 196,90 INR
Mkt. cap
1,02 трлн
Avg. vol.
1,79 млн
Volume
1,76 млн
Dividend
0,65%
Quarterly dividend
2,00 INR
Ex-dividend date
2026-ж., 10-июл.
P/E ratio
31,79
52-wk high
1 414,90 INR
52-wk low
1 101,00 INR
EPS
38,67 INR
Shares outstanding
166,06 млн
No. of employees
28 миң
Related stocks
News stories
From web sources and news partners
The Harvard Law School Forum on Corporate Governance
·
24 мүнөт мурун
CEO and Executive Compensation Practices in the Russell 3000 and S&P 500: 2026
Barron's
·
17 мүнөт мурун
Put the Bull Market’s 4th Birthday Celebrations on Hold
Quartz
·
23 мүнөт мурун
Stock futures mixed ahead of bank earnings, CPI data
Reuters
·
2 саат мурун
Wall Street's big but narrow rally: 4 in 10 S&P stocks are down this year
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 миң
Founded1984
HeadquartersHyderabad, Эндра Прадеш, Индия
SectorPharmaceutical industry
Websitedrreddys.com